drugset / Trial / NCT02315131

Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safety of Inhaled TV46017

NCT02315131 ↗

Phase 1 Terminated 53 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupDouble-blindOther

Summary

The primary objective of the study is to characterize the safety profile and duration of bronchodilation of a single dose of inhaled TV46017

Timeline

Start
2015-03
Primary completion
2015-08
Completion
2015-08

Outcome

Outcome not reported

Stopped (Business): “Business decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject TV46017 Unknown 15 ug Inhaled
Subject TV46017 Unknown 60 ug Inhaled
Subject TV46017 Unknown 120 ug Inhaled
Subject TV46017 Unknown 240 ug Inhaled